ArticleMalaria journal2017
Upon entering an age of global ivermectin-based integrated mass drug administration for neglected tropical diseases and malaria.
Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Strongyloides stercoralis-hookworms association as a path to the estimation of the global burden of strongyloidiasis: A systematic review.PLoS neglected tropical diseases · 2020Pooled it
- Article
- Safety of integrated preventive chemotherapy for neglected tropical diseases.PLoS neglected tropical diseases · 2022Review
- Pharmacokinetic Characterization and Comparative Bioavailability of an Innovative Orodispersible Fixed-Dose Combination of Ivermectin and Albendazole: A Single Dose, Open Label, Sequence Randomized, Crossover Clinical Trial in Healthy Volunteers.Frontiers in pharmacology · 2022Article
- Actions of Camptothecin Derivatives on Larvae and Adults of the Arboviral VectorMolecules (Basel, Switzerland) · 2021Article
- Scabies as a part of the World Health Organization roadmap for neglected tropical diseases 2021-2030: what we know and what we need to do for global control.Tropical medicine and health · 2021Review
- A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool.The American journal of tropical medicine and hygiene · 2020Article
- A discovery and development roadmap for new endectocidal transmission-blocking agents in malaria.Malaria journal · 2018Review
- Mesocosm experiments reveal the impact of mosquito control measures on malaria vector life history and population dynamics.Scientific reports · 2018Article
- Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites.Evolutionary applications · 2018Review
- Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.PLoS neglected tropical diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ivermectin mass drug administration (MDA) in humans to reduce malaria vectors is yet another use for this remarkable medicine whose discoverers shared the 2015 Nobel Prize in Medicine with the discoverer of artemisinin. The malaria community should join those who have long used ivermectin MDA in an integrated battle to break transmission of three vector-borne parasitic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.